RGS2 Suppresses Breast Cancer Cell Growth via a MCPIP1‐Dependent Pathway
暂无分享,去创建一个
S. Baek | Y. Bae | Bin Huang | S. Kang | ChuHee Lee | J. Lyu | Dae-Weon Park | S. Lee | Jingu Lee | Dae‐Weon Park | Chuhee Lee
[1] Jong-Seon Park,et al. RGS2 is a negative regulator of STAT3-mediated Nox1 expression. , 2012, Cellular signalling.
[2] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[3] R. Xiao,et al. Deregulation of RGS2 in cardiovascular diseases. , 2010, Frontiers in bioscience.
[4] A. Sharrocks,et al. Transcription factors Elk-1 and SRF are engaged in IL1-dependent regulation of ZC3H12A expression , 2010, BMC Molecular Biology.
[5] J. M. Wyss,et al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. , 2003, The Journal of clinical investigation.
[6] J. Hurst,et al. Regulator of G-protein signaling (RGS) proteins in cancer biology. , 2009, Biochemical pharmacology.
[7] P. Lin,et al. Rgs2 Mediates Pro-Angiogenic Function of Myeloid Derived Suppressor Cells in the Tumor Microenvironment via Upregulation of MCP-1 , 2011, PloS one.
[8] S. Baek,et al. Role of JAK2–STAT3 in TLR2‐mediated tissue factor expression , 2013, Journal of cellular biochemistry.
[9] N. Dulin,et al. RGS expression in cancer: oncomining the cancer microarray data , 2013, Journal of receptor and signal transduction research.
[10] L. Skalniak,et al. Regulatory feedback loop between NF‐κB and MCP‐1‐induced protein 1 RNase , 2009, The FEBS journal.
[11] Y. E. Chen,et al. Targeted Disruption of MCPIP1/Zc3h12a Results in Fatal Inflammatory Disease , 2013, Immunology and cell biology.
[12] A. Ashworth,et al. Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers , 2007, Breast Cancer Research.
[13] T. Casale,et al. Regulator of G protein signaling 2 is a key modulator of airway hyperresponsiveness. , 2012, The Journal of allergy and clinical immunology.
[14] Jing Wang,et al. MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-κB signaling , 2010, The Journal of experimental medicine.
[15] L. Kirshenbaum,et al. RGS2 inhibits beta-adrenergic receptor-induced cardiomyocyte hypertrophy. , 2010, Cellular signalling.
[16] Zhihui Xie,et al. Phosphorylation of RGS13 by the cyclic AMP-dependent protein kinase inhibits RGS13 degradation. , 2010, Journal of molecular cell biology.
[17] R. Karas,et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure , 2003, Nature Medicine.
[18] S. Akira,et al. mRNA degradation by the endoribonuclease Regnase-1/ZC3H12a/MCPIP-1. , 2013, Biochimica et biophysica acta.
[19] R. Askeland,et al. Regulator of G Protein Signaling 6 (RGS6) Induces Apoptosis via a Mitochondrial-dependent Pathway Not Involving Its GTPase-activating Protein Activity* , 2010, The Journal of Biological Chemistry.
[20] Z. Gatalica,et al. Epigenetic repression of regulator of G‐protein signaling 2 promotes androgen‐independent prostate cancer cell growth , 2012, International journal of cancer.
[21] Qin Wang,et al. Opioid-induced Down-Regulation of RGS4 , 2011, The Journal of Biological Chemistry.
[22] M. Fu,et al. A Novel CCCH-Zinc Finger Protein Family Regulates Proinflammatory Activation of Macrophages* , 2008, Journal of Biological Chemistry.
[23] A. Varshavsky,et al. RGS4 Is Arginylated and Degraded by the N-end Rule Pathway in Vitro * , 2000, The Journal of Biological Chemistry.
[24] Zhihui Xie,et al. RGS16 Inhibits Breast Cancer Cell Growth by Mitigating Phosphatidylinositol 3-Kinase Signaling* , 2009, The Journal of Biological Chemistry.
[25] Michael Reiss,et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. , 2009, Cancer cell.
[26] Haruki Nakamura,et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay , 2009, Nature.
[27] W. McGuire,et al. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Zoltan Szallasi,et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer , 2010, Nature Medicine.
[29] D. Siderovski,et al. The GAPs, GEFs, and GDIs of heterotrimeric G-protein alpha subunits , 2005, International journal of biological sciences.
[30] Jie Huang,et al. Regulator of G protein signaling 6 mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism. , 2011, Cancer research.
[31] Yu Xue,et al. PPSP: prediction of PK-specific phosphorylation site with Bayesian decision theory , 2006, BMC Bioinformatics.
[32] René Bernards,et al. TSPYL5 suppresses p53 levels and function by physical interaction with USP7 , 2011, Nature Cell Biology.
[33] Mahua Choudhury,et al. Monocyte Chemoattractant Protein-1 Induces a Novel Transcription Factor That Causes Cardiac Myocyte Apoptosis and Ventricular Dysfunction , 2006, Circulation research.
[34] R. Neubig,et al. N-Terminal Residues Control Proteasomal Degradation of RGS2, RGS4, and RGS5 in Human Embryonic Kidney 293 Cells , 2007, Molecular Pharmacology.
[35] Min Jae Lee,et al. RGS4 and RGS5 are in vivo substrates of the N-end rule pathway. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[36] V. Quesada,et al. Deubiquitinases in cancer: new functions and therapeutic options , 2012, Oncogene.
[37] R. Neubig,et al. Cardiotonic Steroids Stabilize Regulator of G Protein Signaling 2 Protein Levels , 2012, Molecular Pharmacology.
[38] M. Fu,et al. Genome-Wide Survey and Expression Profiling of CCCH-Zinc Finger Family Reveals a Functional Module in Macrophage Activation , 2008, PloS one.
[39] S. Gygi,et al. Alternative ubiquitin activation/conjugation cascades interact with N-end rule ubiquitin ligases to control degradation of RGS proteins. , 2011, Molecular cell.
[40] R. García-Becerra,et al. Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance , 2012, International journal of molecular sciences.